DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Trillium Therapeutics Inc.

Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. They have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this “do not eat” signal with decoy receptors, they aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.

TÊN CÔNG TY / COMPANY
Trillium Therapeutics Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
TSX (Canada)

MÃ CHỨNG KHOÁN / TICKER
TRIL

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare